Yan Zhou, MD, PhD

Resident, Department of Laboratory Medicine and Pathology

Yan Zhou

Contact Info

Bachelor of Medicine, Peking University Health Science Center, Beijing, 2009

PhD, Pharamceutics, University of Utah, 2014


Yan grew up in a “city of 100 lakes” in northern China and completed her medical training at Peking University Health Science Center in China. She then spent a few years in Utah and California for her PhD degree and research. It was absolutely exciting to move with her family to “land of 10,000 lakes”!! Besides hometown feeling living in Twin Cities, she was immediately attracted by the UMN Residency Program because of great people to work with, the breadth and depth of training in both AP and CP, and nurturing environment. Yan is interested in a couple of specialties such as GI and Dermatopathology, but eager to explore various fields before marrying to any. In her free time, she loves to explore numerous hiking trails along the lakes with her family, whether it is the Mississippi river or St. Croix at the birthplace of Minnesota.

Awards & Recognition

  • Graduate Research Fellowship, University of Utah, 2013-2014



  • Y. Zhou, E. Martinez-Duarte, D. Eleff, L.J. Tafe, J.M. Leibowitz, D.A. Kerr, An unusual hybrid salivary gland tumor: molecular analysis informs the potential pathogenesis of this rare neoplasm, Case Rep. Pathol. 2019 Mar 28;2019:2713234.
  • S. Jiang, Y.L. Franco, Y. Zhou, J. Chen, Nanotechnology in retinal drug delivery, Int. J. Ophthalmol. 11(6), 1038-1044 (2018)
  • R. Zhang, J. Yang, Y. Zhou, P.J. Shami, J. Kope?ek, N-(2-Hydroxypropyl)methacrylamide copolymer-drug conjugates for combination chemotherapy of acute myeloid leukemia, Macromol. Biosci. 16(1), 121-128 (2016).
  • Y. Zhou, J. Yang, R. Zhang, J. Kope?ek, Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel, Eur. J. Pharm. Biopharm. 89, 107-115 (2015).
  • R. Zhang, J. Yang, M. Sima, Y. Zhou, J. Kope?ek, Sequential combination therapy of ovarian cancer with backbone degradable HPMA copolymer paclitaxel and gemcitabine conjugates, Proc. Natl. Acad. Sci. U.S.A 111(33), 12181-12186 (2014).
  • A. Duangjai*, K. Luo*, Y. Zhou*, J. Yang, J. Kope?ek, Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells, Euro. J. Pharm. Biopharm. 87(1), 187-196 (2014). (*, equal contribution).
  • Y. Zhou, J. Yang, J.S. Rhim, J. Kope?ek, HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects, J. Control. Release 172(3), 946-953 (2013).
  • Y. Zhou, J. Kope?ek, Biological Rationale For the Design of Polymeric Anti-Cancer Nanomedicines, J. Drug Target.21(1), 1-26(2013)
  • Y. Zhou, J. Yang, J. Kope?ek, Selective inhibitory effect of HPMA copolymer-cyclopamine conjugate on prostate cancer stem cells, Biomaterials 33, 1863-1872 (2012).
  • Y. Zhou, J. Yang, J. Kope?ek, Cancer stem cells: a potential target for anti-cancer nanomedicines, book chapter in ACS (American Chemical Society) Symposium Series book “Tailored Polymer Architectures for Pharmaceutical and Biomedical Applications”, Washington DC, 2013.